Construction of a Chimeric Gene of Human Papillomavirus Type 16 L1-E7 and Immunogenicity of Expressed Fusion Protein

LIU Chao-qi,XU Xue-mei,XU Jian-qing,LI Kun,SI Jing-yi,LIU Shi-de

DOI: https://doi.org/10.3969/j.issn.1000-8861.2008.03.002

2008-01-01

Abstract:Objective To develop a combined prophylactic and therapeutic vaccine by using a chimeric protein consisting of a C-terminally truncated HPV 16 E7 portion fused to a L1 capsid protein.Methods The HPV16 L1 and E7 genes were obtained from Chinese patients infected with HPV16 using polymerase chain reaction(PCR).The plasmid pET28a(+)-L1-E7c contained L1 ORF and C-terminal portion of E7 ORF was constructed.The expression of the chimeric protein was identified using both HPV16 L1 and E7 specific antibodies by Western blot assay,while the chimeric virus-like particle(cVLP)was observed by the electron microscopy.The immunogenicity of the fusion protein was studied through HPV16 E7 CTL and L1 antibody in HPV16 E7 tumor-carried mouse.Results The plasmid pET28a(+)-L1-E7c was constructed and checked by DNA sequencing and enzyme digestion.The fusion protein of HPV16 L1-E7c was expressed at high level in E.coli.The purified protein was re-natured and able to self-assemble into chimeric virus-like particle(cVLP)in vitro,which is morphologically indistinguishable from the native virion under the electron microscope.Vaccination with HPV16 L1-E7c induced regression of established tumors expressing HPV16 E7.And the fusion protein was a potent inducer of HPV16 E7 CTL responses and HPV16 L1 antibody.Conclusion The HPV16 L1-E7c fusion protein can be expressed in high level and self-assembled into the chimeric virus-like particles in vitro,which indicates that cVLP are suitable for prevention and therapy of HPV16 infection and related tumors.